Molecular Cancer Therapeutics: 17 (3)

Highlights

Highlights

Highlights of This Issue

Mol Cancer Ther March 1 2018 17 (3) 589-589;

Review

Review

Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer

Bayley A. Jones, Sooryanarayana Varambally and Rebecca C. Arend

Mol Cancer Ther March 1 2018 17 (3) 591-602; DOI:10.1158/1535-7163.MCT-17-0437

Small Molecule Therapeutics

Small Molecule Therapeutics

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury

Paola Magnaghi, Barbara Salom, Liviana Cozzi, Nadia Amboldi, Dario Ballinari, Elena Tamborini, Fabio Gasparri, Alessia Montagnoli, Laura Raddrizzani, Alessio Somaschini, Roberta Bosotti, Christian Orrenius, Fabio Bozzi, Silvana Pilotti, Arturo Galvani, Josh Sommer, Silvia Stacchiotti and Antonella Isacchi

Mol Cancer Ther March 1 2018 17 (3) 603-613; DOI:10.1158/1535-7163.MCT-17-0324
Small Molecule Therapeutics

Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia

Noelia Puente-Moncada, Paula Costales, Isaac Antolín, Luz-Elena Núñez, Patricia Oro, Maria Ana Hermosilla, Jhudit Pérez-Escuredo, Nicolás Ríos-Lombardía, Ana M. Sanchez-Sanchez, Elisa Luño, Carmen Rodríguez, Vanesa Martín and Francisco Morís

Mol Cancer Ther March 1 2018 17 (3) 614-624; DOI:10.1158/1535-7163.MCT-17-0530
Small Molecule Therapeutics

NEO212 Inhibits Migration and Invasion of Glioma Stem Cells

Nagore I. Marín-Ramos, Thu Zan Thein, Hee-Yeon Cho, Stephen D. Swenson, Weijun Wang, Axel H. Schönthal, Thomas C. Chen and Florence M. Hofman

Mol Cancer Ther March 1 2018 17 (3) 625-637; DOI:10.1158/1535-7163.MCT-17-0591

Large Molecule Therapeutics

Large Molecule Therapeutics | AuthorChoice

An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer

Sunil Bhakta, Lisa M. Crocker, Yvonne Chen, Meredith Hazen, Melissa M. Schutten, Dongwei Li, Coenraad Kuijl, Rachana Ohri, Fiona Zhong, Kirsten A. Poon, Mary Ann T. Go, Eric Cheng, Robert Piskol, Ron Firestein, Aimee Fourie-O'Donohue, Katherine R. Kozak, Helga Raab, Jo-Anne Hongo, Deepak Sampath, Mark S. Dennis, Richard H. Scheller, Paul Polakis and Jagath R. Junutula

Mol Cancer Ther March 1 2018 17 (3) 638-649; DOI:10.1158/1535-7163.MCT-17-0813
Large Molecule Therapeutics | AuthorChoice

A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs)

Michael L. Miller, Manami Shizuka, Alan Wilhelm, Paulin Salomon, Emily E. Reid, Leanne Lanieri, Surina Sikka, Erin K. Maloney, Lauren Harvey, Qifeng Qiu, Katie E. Archer, Chen Bai, Dilrukshi Vitharana, Luke Harris, Rajeeva Singh, Jose F. Ponte, Nicholas C. Yoder, Yelena Kovtun, Katharine C. Lai, Olga Ab, Jan Pinkas, Thomas A. Keating and Ravi V.J. Chari

Mol Cancer Ther March 1 2018 17 (3) 650-660; DOI:10.1158/1535-7163.MCT-17-0940
Large Molecule Therapeutics

Molecularly Targeted Cancer Combination Therapy with Near-Infrared Photoimmunotherapy and Near-Infrared Photorelease with Duocarmycin–Antibody Conjugate

Tadanobu Nagaya, Alexander P. Gorka, Roger R. Nani, Shuhei Okuyama, Fusa Ogata, Yasuhiro Maruoka, Peter L. Choyke, Martin J. Schnermann and Hisataka Kobayashi

Mol Cancer Ther March 1 2018 17 (3) 661-670; DOI:10.1158/1535-7163.MCT-17-0851
Large Molecule Therapeutics

Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers

Divya Sakamuri, Isabella C. Glitza, Sonia L. Betancourt Cuellar, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Jennifer J. Wheler, David S. Hong, Aung Naing, Gerald S. Falchook, Michelle A. Fanale, Maria E. Cabanillas and Filip Janku

Mol Cancer Ther March 1 2018 17 (3) 671-676; DOI:10.1158/1535-7163.MCT-17-0673
Large Molecule Therapeutics

Intratumoral Payload Concentration Correlates with the Activity of Antibody–Drug Conjugates

Donglu Zhang, Shang-Fan Yu, S. Cyrus Khojasteh, Yong Ma, Thomas H. Pillow, Jack D. Sadowsky, Dian Su, Katherine R. Kozak, Keyang Xu, Andrew G. Polson, Peter S. Dragovich and Cornelis E.C.A. Hop

Mol Cancer Ther March 1 2018 17 (3) 677-685; DOI:10.1158/1535-7163.MCT-17-0697

Cancer Biology and Translational Studies

Cancer Biology and Translational Studies

Scavenger Receptor Type B1 and Lipoprotein Nanoparticle Inhibit Myeloid-Derived Suppressor Cells

Michael P. Plebanek, Debayan Bhaumik, Paul J. Bryce and C. Shad Thaxton

Mol Cancer Ther March 1 2018 17 (3) 686-697; DOI:10.1158/1535-7163.MCT-17-0981
Cancer Biology and Translational Studies

Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors

Apurva K. Srivastava, Melinda G. Hollingshead, Jeevan Prasaad Govindharajulu, Joseph M. Covey, Dane Liston, Melanie A. Simpson, James O. Peggins, Donald P. Bottaro, John J. Wright, Robert J. Kinders, James H. Doroshow and Ralph E. Parchment

Mol Cancer Ther March 1 2018 17 (3) 698-709; DOI:10.1158/1535-7163.MCT-17-0552

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma

Conor E. Steuer, Christopher C. Griffith, Sreenivas Nannapaneni, Mihir R. Patel, Yuan Liu, Kelly R. Magliocca, Mark W. El-Deiry, Cynthia Cohen, Taofeek K. Owonikoko, Dong M. Shin, Zhuo G. Chen and Nabil F. Saba

Mol Cancer Ther March 1 2018 17 (3) 710-716; DOI:10.1158/1535-7163.MCT-17-0504

Main menu

User menu

Search

Table of Contents

Highlights

Review

Small Molecule Therapeutics

Large Molecule Therapeutics

Cancer Biology and Translational Studies

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Issue Highlights

Jump to

Articles

Info for

About MCT